Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Recent News

  • Therma Bright schließt eine Vereinbarung mit Orpheus zur gemeinsamen Entwicklung des COVID-19 Speichel-Schnelltests von Orpheus Medica, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - Freitag, 28. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, eine endgültige Vereinbarung zur gemeinsamen Entwicklung mit Orpheus Medica Inc. ("Orpheus") oder (Therma & Orpheus, die "Parteien") unterzeichnet zu haben. Diese Vereinbarung eröffnet Therma Zugang zu der neuen biologischen Plattform von Orpheus und ermöglicht die gemeinsame Entwicklung eines Speichel-Schnelltests zum Screening und Nachweis des Virus (SARS-CoV-2), das COVID-19 verursacht. Im Rahmen dieser Vereinbarung wird...

    2020-08-28 9:01 AM ET
  • Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19. Under this agreement,...

    2020-08-27 9:07 AM ET
  • Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.

    Toronto, Ontario--(Newsfile Corp. - August 26, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction for $425,000. The transaction includes the acquisition of...

    2020-08-26 5:00 AM ET
  • Update von Therma Bright zu den Transaktionen Saringer und Orpheus

    Toronto, Ontario--(Newsfile Corp. - Donnerstag, 20. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizingeräteunternehmen, gibt hiermit ein Update in Erwiderung auf Anfragen von Aktionären. Saringer - Akquise von Vermögenswerten (Benepod®-Schmerzlinderungstechnologie)Wie bereits zuvor angekündigt (siehe Pressemitteilungen vom 15. Januar, 8. April und 9. Juli 2020), hat Therma eine zufriedenstellende Due Diligence-Prüfung abgeschlossen und beabsichtigt, die Benepod®-Schmerzlinderungstechnologie und andere damit verbundene medizinische Gerätetechnologien sowie geistiges Eigentum von Saringer Life Science Technologies Inc. ("

    2020-08-20 4:17 PM ET
  • Therma Bright Provides Corporate Update on the Saringer and Orpheus Transactions

    Toronto, Ontario--(Newsfile Corp. - August 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides this corporate update in response to inquiries from shareholders. Saringer - Asset Acquisition (Benepod® pain relief technology)As previously announced (refer to news releases of January 15, April 8 & July 9, 2020), Therma has completed satisfactory due diligence and intends to acquire Benepod® pain relief technology and other related medical device technology and intellectual property...

    2020-08-20 5:00 AM ET
  • Therma Bright Schließt Die Due-Diligence-Prüfung des COVID-19-Speichelschnelltests CoviSafe(TM) von Orpheus Medica Ab Und Geht in Phase 2 über

    Toronto, Ontario--(Newsfile Corp. - Freitag, 14. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, dass es die erste Phase seiner Due Diligence-Prüfung für die Plattformtechnologie von Orpheus Medica ("Orpheus") abgeschlossen hat und die Entwicklung eines Speichelschnelltests (CoviSafe™) zum Nachweis des Virus (SARS-CoV-2), das COVID-19 verursacht, plant. CoviSafe™ wird die neuartigen Biologika und fortschrittlichen Computerplattformen von Orpheus in Verbindung mit Gerätetechnologie von Drittanbietern integrieren, um einen zuverlässigen, handflächengroßen...

    2020-08-14 12:00 AM ET
  • Therma Bright Completes Due Diligence of Orpheus Medica's CoviSafe(TM) COVID-19 Rapid Saliva Test and Moves to Phase 2

    Toronto, Ontario--(Newsfile Corp. - August 13, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed its Phase 1 due diligence on Orpheus Medica's ("Orpheus") platform technology and plan for the development of a rapid saliva test (CoviSafe™) for the detection of the virus (SARS-CoV-2) causing COVID-19. CoviSafe™ will integrate Orpheus' novel biologics and advanced computational platforms, coupled with third party device technology, to...

    2020-08-13 5:00 AM ET
  • Therma Bright Announces Closing of Over-Subscribed Private Placement for $1,250,000

    Toronto, Ontario--(Newsfile Corp. - August 6, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, announces that it has completed the closing of its non-brokered private placement (the "Offering") previously announced on July 20, 2020 and increased July 22, 2020. The Company has issued 16,666,667 units for gross proceeds of $1,250,000. No finder's fee was paid in conjunction with the Offering. All securities issued are subject to a...

    2020-08-06 4:00 PM ET